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Purpose: To clarify the association between disturbed 
thyroid hormone metabolism (low T3 syndrome) and re-
lease of cytokines and markers of cell-mediated im-
mune response.
Material and Methods: Concentrations of cytokines as 
well as of thyroid hormones were determined in 32 pa-
tients suffering from severe traumatic brain injury: in-
terleukin-(IL-)1, IL-6, IL-10, tumor necrosis factor, trans-
forming growth factor-(TGF-)β, soluble interleukin-2 
receptor (sIL-2R), neopterin, and β2-microglobulin (β2m) 
in serum and cerebrospinal fluid; triiodothyronine (T3), 
free T3, thyroxine (T4), free T4, thyrotropin, thyrox-
ine-binding globulin, and albumin in serum. Addition-
ally, clinical parameters were assessed: Glasgow Coma 
Score, CT scan, intracranial pressure, Glasgow Outcome 
Score, and occurrence of pneumonia.
Results: Among 31 patients with a low T3 syndrome, 
those with additional low serum T4 levels (n = 13) showed 
a prolonged suppression of serum β2m, neopterin, and 
sIL-2R, and a higher secondary increase of serum β2m, 
neopterin, and TGF-β, as well as lower T3 levels (all 
p < 0.05). These patients also had a longer stay in the 
intensive care unit (34 ± 6 days vs. 22 ± 12 days; 
p = 0.008). Increased levels of β2m correlated with a pre-
ceding decrease of thyrotropin (cerebrospinal fluid: 
r = –0.53; p = 0.004; serum: r = –0.41; p = 0.029). Associa-
tions of thyroid hormone metabolism with either other 
cytokines or with clinical parameters were not detected.
Conclusion: These results show that low T3 syndrome is 
a very common pathophysiological feature after severe 
traumatic brain injury. The association of a low T3 syn-
drome in combination with low serum T4 levels, with an 
altered time course of markers of cell-mediated immu-
nity led the authors to hypothesize that a disturbed 
thyroid hormone metabolism may be interrelated with 
a prolonged cellular immune dysfunction after trau-
matic brain injury.
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Introduction
Alterations in thyroid hormone metabolism and regula-
tion occur in virtually all patients admitted to the inten-
sive care unit, irrespective of a preexisting thyroidal dis-
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ease. These alterations are mainly characterized by a 
decrease in serum triiodothyronine (T3) levels (low T3), 
while an additional drop in serum thyroxine (T4) may 
occur in the clinically more severe cases (low T3-low T4), 
which is associated with an increased mortality rate [1, 
2]. The reduced T3 and/or T4 levels are associated with 
normal or low serum thyrotropin values. The etiology of 
this disturbance is only partially understood. Changes 
within the central nervous system (CNS) as well as in 
the periphery were charged causal, like decreased pro-
duction of hypothalamic thyrotropin-releasing hor-
mone, decreased generation of T3 by liver thyroxin de-
iodinase type 1, altered serum transport capacity by 
thyroxin-binding globulin (TBG), or a T3/T4 tissue 
transport defect [1, 2]. This endocrine disturbance has 
been given different names, such as the “low T3 syn-
drome”, “euthyroid sick syndrome”, or “non-thyroidal 
illness syndrome” and there is still disagreement on the 
terminology, reflecting the unresolved pathophysiology 
of these changes and the still open question of a true tis-
sue hypothyroidism [1–3]. In our study, we prefer to use 
the more descriptive term “low T3 syndrome”, thus 
avoiding inferences on function or mechanisms.
Cytokines represent a group of locally and systemi-
cally released inflammatory proteins held responsible for 
changes in the hypothalamic-pituitary-thyroid axis equal 
to those found in low T3 syndrome (for review see [4]). 
The list of factors investigated includes pro-inflammatory 
(tumor necrosis factor [TNF], interleukin-[IL-]1, IL-6) 
and anti-inflammatory cytokines (IL-10) as well as mark-
ers of mononuclear cell activation (soluble interleukin-2 
receptor [sIL-2R]) [4–6]. In particular, serum IL-6 con-
centrations were shown to correlate with low T3 levels in 
clinical studies enrolling patients with a large spectrum of 
disorders [7–9]. However, this issue is questioned by re-
cent studies in which neutralization of cytokine activity 
failed to prevent the low T3 syndrome following lipopoly-
saccharide challenge [10–12]. Many of the clinical studies 
are cross-sectional and limited to predefined serum sam-
pling, thus possibly missing time effects, and they exclude 
the central nervous compartment that is pivotal in the 
regulation of the hypothalamic-pituitary-thyroid axis. 
Based on these premises, individuals with severe trau-
matic brain injury (TBI) represent an interesting sub-
group of patients for studying the low T3 syndrome in 
humans, since they are usually healthy until the defined 
beginning of the disease at the time of injury, and since 
the peripheral as well as the central nervous compart-
ment are accessible. The low T3 syndrome is a common 
component of the pathophysiology of severe TBI [13–18], 
and the release of different cytokines such as IL-6, IL-10, 
TNF or pleiotropic transforming growth factor-(TGF-)β 
into serum and cerebrospinal fluid (CSF) has previously 
been shown in these patients [19–21], suggesting a possi-
ble physiological link between these cascades.
In the present study we therefore investigated the 
interrelation of thyroid hormone levels with cytokine 
levels in serum and CSF as well as with other clinical 
data in patients suffering from severe TBI. We have se-
Table 1. Epidemiologic and clinical data of 32 patients with severe trau-
matic brain injury.
Patient # Sex Age  GCSa CTb ICPc GOSd Pneumoniae
  (years)   (mmHg)     
  1 Male 21   3 DI IV° 140 1     (5)     
  2 Female 59 10 EML   87 1     (7)     
  3 Male 42   3 NEML 108 1     (9)     
  4 Male 67   5 EML   21 1   (10)     
  5 Male 35   8 DI III° 110 1   (10)     
  6 Male 23   3 NEML   86 1   (12) x    
  7 Male 73   6 DI II°   11 1 (104)     
  8 Male 27   3 DI II°   25 3     
  9 Male 53   3 DI II°   29 3 x    
10 Male 56   5 EML   24 3     
11 Male 22   5 DI II°   19 3 x    
12 Male 26   5 DI II°   42 3     
13 Female 51   5 DI II°   35 3     
14 Male 21   3 DI II°   10 4     
15 Male 26   4 DI II°   56 4 x    
16 Female 31   5 DI II°   31 4 xf    
17g Male 45   6 DI II°   29 4     
18 Male 48   8 DI III°   41 4     
19 Male 17   8 DI II°   19 4     
20 Male 31 11 EML   33 4 x    
21 Male 48 12 EML   89 4     
22 Male 18   3 DI II°   34 5 x    
23 Male 42   3 DI II°   28 5 x    
24 Male 55   5 EML   24 5     
25 Female 17   6 DI II°   25 5 x    
26 Male 41 10 DI II°   24 5 x    
27 Female 35 11 DI II°   12 5     
28 Female 23 12 DI II°   43 5     
29 Female 25 14 EML   30 5     
30 Male 16 14 EML   28 5     
31 Female 34 14 DI II°   26 5     
32 Male 59 14 DI II°   40 5 x  
a GCS: Glasgow Coma Score [56]
b  CT: classification of computed tomography of the brain at admission [30]: DI 
II°–IV°: diffuse injury grade II–IV; EML: evacuated mass lesion; NEML: nonevacu-
ated mass lesion
c  ICP: maximal intracranial pressure persisting for > 5 min
d  GOS: Glasgow Outcome Score [31]: 1: dead, 3: severely disabled, 4: moderately dis-
abled, 5: good recovery; numbers in brackets: days of survival
e  Pneumonia: diagnosis was made if the following criteria were met: pulmonary infil-
trates; signs of inflammation (fever, increased serum levels of C-reactive protein, 
leukocytosis); detection of pathogens in tracheal/bronchial material. This was re-
quired for antibiotic treatment. Drugs were not administered on a routine prophy-
lactic regimen
f This patient suffered from Pseudomonas sepsis
g patient without low T3 syndrome
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lected a group of pro- and anti-inflammatory cytokines, 
some of which have been investigated in previous stud-
ies although using serum samples only [4–6]. Since 
T-lymphocyte-derived sIL-2R has been shown to cor-
relate with the extent of low T3 syndrome [5, 22] and due 
to the fact that thyroid hormones themselves influence 
cellular immune functions [23, 24], we measured further 
lymphocyte counts and mononuclear cell activation 
markers (i.e., neopterin, β2-microglobulin [β2m)). Ne-
opterin is synthesized by stimulated monocytes/macro-
phages [25], and β2m is released by activated lympho-
cytes and neutrophils [26, 27].
Material and Methods
Patients and Sampling of Serum and CSF
In this observational study, 32 patients were enrolled 
with the primary diagnosis of severe TBI (see Table 1). 
Exclusion criteria were the following: systemic injuries 
requiring further treatment, i.e., long-bone or spine 
fractures, and visceral damage; known or suspected pre-
existing thyroid or pituitary/hypothalamic disorders; 
general medical conditions requiring drugs known to 
interfere with thyroid hormone metabolism or regula-
tion; steroid treatment. According to a standardized 
protocol, all patients received indwelling ventricular 
catheters for the monitoring and treatment of increased 
intracranial pressure (ICP) [28]. All patients were en-
terally tube-fed thus avoiding “fasting”, and received 
low-dose dopamine (3 µg/kg/min) for renal support. 
Blood and CSF were taken on admission (day 0) and 
daily between 07:00 and 09:00 a.m. thereafter. Samples 
were either processed directly (thyroid parameters) or 
centrifuged at 170×g for 10 min at 4 °C and supernatants 
were frozen at –80 °C until analyzed. Sample collection 
was performed up to 3 weeks after trauma or until re-
moval of the intraventricular cathe-
ter when ICP remained stable ≤ 15 
mmHg for 24 h. Glasgow Coma 
Score (GCS) [29] was documented 
on the scene. Computed tomogra-
phy (CT) of the brain was performed 
at admission and classified accord-
ing to Marshall et al. [30]. Maximal 
ICP levels persisting for > 5 min 
were recorded daily, and pneumonia 
was diagnosed as described in Table 
1. Total lymphocyte counts were as-
sessed daily using an automatized 
cell counter (Technicon H*1, Bayer 
Diagnostics GmbH, Munich, Germany). Time from 
trauma until discharge from the intensive care unit was 
recorded, and clinical outcome was assessed at 6 months 
after injury using the Glasgow Outcome Score (GOS) 
[31]. The Zurich University Hospital Medical Ethics 
Board approved the protocol and waived the need for 
informed consent.
Measurement of Cytokines and Thyroid Hormones
Cytokines and inflammatory mediators as well as thyroid 
hormones were analyzed using commercially available 
assays. Thyroid parameters (T3, T4, FT3 [free T3], FT4 
[free T4], thyrotropin) were measured by chemilumines-
cence (ACS:180, Ciba Corning Diagnostics AG, Diet-
likon, Switzerland). A radioimmunoassay was used for 
TBG (CIS bio international, Gif-sur-Yvette, France), 
and albumin levels were determined by laser photometry 
(BNA Automat, Behring Werke, Marburg, Germany). 
Besides neopterin (radioimmunoassay), all cytokines/
leukocyte activation markers were measured by ELISA 
(Table 2). The time course of cytokine concentrations in 
CSF and serum after TBI has been previously described 
in detail for IL-6 [20], TGF-β [21], TNF, IL-10 [19], 
sIL-2R, β2m, and neopterin [32]. Here, these data were 
complemented by analyzing peak concentrations and the 
corresponding days of maximal levels for each patient. 
Due to limitations in the amounts of CSF obtained, com-
plete analyses could not be performed in all patients.
Data Analysis
Statistical analysis was performed using a commercially 
available data analysis system (StatView®5.0, SAS Insti-
tute Inc., Cary, NC, USA). Due to the organization of 
the data, serial measurements were analyzed using sum-
mary measures, i.e., peak values and time to maximum/
Table 2. List of assays used for analysis of cytokines/leukocyte activation markers in serum and 
cerebrospinal fluid. (n) gives the number of brain-injured patients in whom the amount of se-
rum and cerebrospinal fluid was sufficient for a determination throughout the study. β2m: 
β2-microglobulin; IL: interleukin; sIL-2R: soluble interleukin-2 receptor; TGF: transforming 
growth factor; TNF: tumor necrosis factor.
Parameter (n) Source Detection limit
β2m (30) Medizintechnik GmbH, Freiburg, Germany 0.11 pg/ml
IL-1β R&D Systems, Minneapolis, MN, USA 0.3 pg/ml
sIL-2R (31) T-Cell Sciences Inc., Cambridge, MA, USA 0.1 U/ml
IL-6 (32) R&D Systems, Minneapolis, MN, USA 0.35 pg/ml
IL-10 (24) Biosource, Camarillo, CA, USA 0.2 pg/ml
Neopterin (30) Ges. für Immunchemie und -biologie mbH, Freiburg, Germany 0.1 ng/ml
TGF-β1 (19) Genzyme, Cambridge, MA, USA 50 pg/ml
TNF (30) NBS Biologicals, Cambs, UK 0.09 pg/ml
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minimum response for thyroid hor-
mones and cytokines [33]. Due to dif-
ferent time periods during which mea-
surements were performed for each 
patient, an area-under-curve analysis 
was not applicable. Dichotomized out-
come variables were GOS (favorable: 
GOS 4 or 5, vs. unfavorable: GOS 1–3) 
and low T3 syndrome state (low T3 vs. 
low T3-low T4). Data were analyzed us-
ing Fisher’s exact test, Mann-Whitney 
U-test, Wilcoxon signed rank test, 
Spearman rank correlation and multi-
ple regression as appropriate. For mul-
tiple logistic regression, patients were 
grouped into low- or high-level re-
sponders according to their maximum 
cytokine concentrations being below 
or above the median value, respective-
ly. Values were log-transformed for 
multiple stepwise backward regression 
as appropriate. A significance level for 
α < 0.05 was used throughout all tests. 
Data are given as mean ± standard de-
viation (SD), unless stated otherwise.
Results
Among the 32 patients investigated 
(37.1 ± 15.8 years; 24 male, eight fe-
male), only one showed normal levels 
for all thyroid parameters besides FT3 
(2.5 pmol/l, normal ≥ 3.5 pmol/l). This 
individual seemed not to suffer from 
TBI-associated low T3 syndrome and 
was excluded from further analyses in 
order to obtain a homogeneous study 
group (low T3 vs. low T3-low T4). All 
other 31 patients showed T3 and FT3 
levels below the normal range at any 
time after TBI (Figure 1). Decreased 
serum concentrations were observed 
for T4 and FT4 in 13 and 21 individuals, respectively. El-
evation of FT3 concentrations was not observed in the 
early time period. Patients with low T3-low T4 showed 
lower T3 concentrations than patients with low T3 only 
(p = 0.005; Figure 1), while minimal T3 levels were 
reached almost simultaneously in both groups. Thyro-
tropin showed decreased levels in twelve patients, re-
mained normal during the whole study period in 16, and 
increased later on in six patients. Decreased thyrotropin 
concentrations were not associated with the lowest T3 or 
T4 levels. Albumin and TBG levels remained within the 
normal ranges during the whole study period in almost all 
patients. Lymphocyte counts were below the normal 
range (1,500–4,000/µl) in all patients investigated with a 
mean lowest number of 580 ± 200/µl (range 320–1,140/µl) 
and a nadir at day 4.8 ± 3.2 (range 0–11). A favorable 
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Figure 1. Serum concentrations of thyroid hormones and thyrotropin of 31 patients with low T3 
syndrome up to 3 weeks after traumatic brain injury. Scatter plots show the minimal concen-
tration versus the day of the minimal level of the respective parameter for each patient. For 
thyrotropin also maximal values after secondary increase are shown (Thyrotropinmax). One 
data point is shown for each patient. Normal ranges are outlined by black bars on the right. 
Levels below the normal range were found for free triiodothyronine in all patients. A more se-
vere low T3-low T4 syndrome was detected in 13 patients. Data are split by clinical outcome: 
closed circles = favorable, i.e., Glasgow Outcome Score 4/5; open circles = unfavorable, i.e., 
Glasgow Outcome Score 1–3. No significant differences were found between both groups.
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outcome was found in 18 out of 31 patients. No correla-
tion was detected between GCS, or GOS, and low T3 
state. However, considering survivors only, patients 
with low T3-low T4 remained signifi-
cantly longer at the intensive care 
unit (33.8 ± 5.6 days) as compared to 
those with low T3 only (22.2 ± 12.4 
days; p = 0.008). Almost all patients 
(28/31) suffered from increased ICP, 
and diagnosis of pneumonia as a typi-
cal systemic infectious complication 
was made in one third (11/31) of the 
TBI victims (see Table 1). Statistical-
ly significant associations were absent 
among these parameters (i.e., ICP, 
pneumonia) or CT classification and 
peak values of thyroid hormones or 
cytokines.
IL-1 concentrations showed no 
consistent pattern of increase, neither 
in serum nor in CSF. Only sporadic 
peaks were observed, and thus this 
parameter was excluded from further 
statistical analyses. According to the 
time of maximal levels, inflammatory 
markers could be classified as imme-
diate (IL-10 CSF and serum, IL-6 
CSF, and TGF-β CSF), prolonged 
(TNF CSF and serum, IL-6 serum, 
sIL-2R CSF, β2m CSF, and neopterin 
CSF), or delayed responders (sIL-2R, 
β2m, neopterin, and TGF-β, all in se-
rum; Figures 2a and 2b). In particular 
for the last group, the peak levels ap-
peared significantly later than the 
minimal levels of T3, T4, or thyrotro-
pin, i.e., the cytokines peaked after the 
minima of the hormone levels (p < 
0.05). Similarily, thyrotropin reached 
its minimal levels before β2m, neop-
terin, and TNF peaked in CSF (p < 
0.05).
Additionally, we investigated 
whether a more severe low T3 syn-
drome (i.e., low T3-low T4) may be 
associated with an increased or pro-
longed release of pro- or anti-
inflammatory parameters. Higher se-
rum levels were observed of β2m, 
neopterin, and TGF-β in low T3-low T4 as compared 
to low T3 alone (p = 0.006, p = 0.009, and p = 0.023, re-
spectively; Figures 2a and 2b). Maximum levels were 
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Figures 2a and 2b. Maximal concentrations of a) cytokines (interleukin-[IL-]6, tumor necrosis 
factor [TNF], transforming growth factor-[TGF-]β) and b) markers of cellular immune activa-
tion (β2-microglobulin, soluble interleukin-2 receptor [sIL-2R], neopterin) in cerebrospinal fluid 
(CSF) and serum up to 3 weeks after traumatic brain injury. Scatter plots show the maximal 
concentration versus the day when the respective parameter reached its maximal level for 
each patient. One data point is shown for each patient. Lines indicate upper limits of normal 
ranges. For IL-6, all patients showed increased concentrations at any time. Normal values for 
this cytokine were below the range depicted in the graphic. Data are divided according to the 
T3 state: closed circles = low T3; open circles = low T3-low T4. Parameters showing significant 
differences (p < 0.05) between these two groups are labeled (†); cf. also the Results section.
Figures 2b. See next page.
a
Hans VH, et al. Low T3 Syndrome after Head Injury
364 European Journal of Trauma 2005 · No.  4  © Urban & Vogel
reached significantly later in pa-
tients with low T3-low T4 of β2m, 
neopterin, and sIL-2R in serum 
(p = 0.019, p = 0.015, and p = 0.015, 
respectively), and of neopterin and 
TNF in CSF (p = 0.016 and p = 0.038, 
respectively).
To investigate the potential role 
of cytokines in modulating the on-
set and severity of the low T3 syn-
drome, we only used cytokines 
peaking early after TBI or simulta-
neously with thyroid parameters for 
multiple logistic regression. Neither 
these calculations nor separately 
performed Fisher’s exact test re-
vealed any association of cytokine 
release with the low T3 syndrome. 
The latter tests were performed to 
increase the chances to detect any 
differences. Changes in thyrotropin 
concentrations could not be asso-
ciated with cytokine levels in the 
patients investigated (multiple step-
wise backward regression). How-
ever, increased levels of β2m corre-
lated with a preceding decrease of 
thyrotropin (CSF: ρ = –0.528; p = 
0.004; serum: ρ = –0.414; p = 0.029; 
Spearman rank). Altogether, there 
was no independent association be-
tween any of the cytokine measure-
ments and the measurements of ei-
ther circulating thyroid hormones 
or thyrotropin.
Discussion
In this study, we have characterized a group of 32 patients 
with isolated severe TBI with regard to thyroid hormonal 
status and to cytokine levels in CSF and in serum from 
the day of trauma up to 3 weeks post injury. Our data cor-
roborate previous findings, demonstrating altered thy-
roid hormone metabolism in TBI patients [13, 14, 17, 18]. 
Only one patient did not present with a low T3 syndrome. 
The reason for this single outlier, unfortunately, remains 
unclear, since none of the clinical and physiological pa-
rameters recorded for these patients did explain the ab-
sence of an altered thyroid hormonal status in this one 
patient. Serum T3 levels were below the normal range in 
31 patients and an additional decrease of T4 was observed 
in 13 of them. Decreased concentrations of thyrotropin 
were detected during the first week in twelve patients. 
Since the mechanisms causing these changes are a matter 
of debate [1, 2, 4], we monitored cytokine concentrations 
in CSF and in serum of these patients in order to investi-
gate a putative impact of an intrathecal or peripheral in-
flammatory response on the low T3 syndrome.
The major finding of our study was a delayed and 
marked increase of markers of leukocyte activation, 
mainly β2m and neopterin, but also of sIL-2R and 
TGF-β. These markers showed a later or more intense 
10
5
0
10
1
0.1
0.01
0.001
1000
100
10
1
10
5
0
100
10
1
0.1
0.01
100
10
1
0.1
CSF Serum
β 2-
m
ic
ro
gl
ob
ul
in
 (m
g/
l)
sI
L-
2R
 (U
/l)
N
eo
pt
er
in
 (µ
g/
l)
Days after injury Days after injury
0 5 10 15 20
0 5 10 15 20 0 5 10 15 20
0 5 10 15 20 0 5 10 15 20
0 5 10 15 20
b
Figures 2a and 2b. Legend see page 363.
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increase in more severely ill patients (i.e., low T3-low 
T4), even though the time point (day post trauma) of 
minimal T3 levels did not differ between both groups 
(low T3 vs. low T3-low T4). Similarly, β2m showed a 
stronger increase when thyrotropin was more sup-
pressed at earlier time points.
Head injury is followed by an almost immediate 
drop of lymphocyte numbers that is accompanied by a 
deficit in T-cell activation and decreased CD25 expres-
sion. These changes seem to persist up to several weeks 
after TBI [21, 34, 35]. β2m is a small glycoprotein and 
elevated levels of the soluble form are thought to reflect 
the release by activated lymphocytes and neutrophils 
[26, 27]. Neopterin is synthesized and released exclu-
sively by monocytes/macrophages upon stimulation 
with interferon-(IFN-)γ and is thus considered an acti-
vation marker of T-cells in a number of disorders [25]. 
IL-2R-α is expressed on T- and B-cells as well as on 
monocytes/macrophages and is shed in a soluble form 
from the T-cell membrane upon stimulation. It is not 
only a sensitive and quantitative marker for mononucle-
ar cell activation but may also inhibit effects of IL-2 by 
scavenging [22].
In part, the increase of these activation markers may 
be due to a secondary rise in neutrophil granulocyte 
counts, whereas monocyte numbers showed no signifi-
cant changes after TBI [20]. At the same time, T-cell 
numbers and function remain suppressed for up to 3 
weeks after injury [21, 34, 35]. However, elevations of 
sIL-2R and neopterin, representing a sustained activa-
tion of the IFN-γ and TNF pathways, are not necessarily 
synonymous for an efficient immune response [36]. Al-
though our data indicate a negative correlation between 
serum T3 and sIL-2R, similarly to the findings by Boelen 
et al. [5], we disagree with their conclusion implicating 
the low T3 syndrome as the consequence rather than the 
cause of activation of the cytokine network. Our long-term 
longitudinal study clearly demonstrated that the increase 
of activation markers occurred after the drop of thyroid 
hormones. Therefore, it would be more appropriate to 
hypothesize that a suppression of T-cells was due to low-
ered T3/T4 levels after TBI. Recently, it has become clear 
that T3 exerts pleiotropic effects on the thymus by induc-
ing thymocyte proliferation and release from thymic 
nurse cells [37]. Strong evidence also exists for a modula-
tion of serum sIL-2R levels by thyroid hormones [23, 24]. 
An action of thyroid hormones on thymic function in 
head-injured patients was suggested by the observation 
that low T3 levels correlated with decreased thymulin 
concentrations [38]. The molecular associations observed 
in this study together with previous experimental find-
ings may therefore indicate an endocrinological deficien-
cy (i.e., hypothyroidism) following TBI [1], which may 
cause abnormalities in cell-mediated immunity and thus 
a posttraumatic immunodeficiency [21, 34, 35, 38]. On the 
other hand, low T3 serum concentrations in conjunction 
with elevated IL-10 and TGF-β levels [19, 21] may also be 
part of an anti-inflammatory reaction to TBI, preventing 
uncontrolled inflammatory tissue damage [39].
We could not detect any statistical correlation sup-
porting a causative role of cytokines for the development 
of the low T3 syndrome. Cytokine release within the CNS 
as well as in the periphery is now an accepted component 
of the pathophysiology of TBI with IL-6 playing a particu-
larly important role [40]. Experimental investigations and 
clinical studies demonstrated an interrelation between cy-
tokines such as IL-1, IL-6, or TNF and the low T3 syndrome 
[4, 5, 8, 9, 16]. Recently, such a role of cytokines in the 
pathogenesis of low T3 syndrome has been challenged. At 
least the early phase of low T3 syndrome seemed not to be 
caused by IL-6, since changes in thyroid hormones pre-
ceded increased cytokine levels in surgical patients [41]. 
Moreover, endotoxin-induced low T3 syndrome was not 
attenuated when IL-1, IL-6, or TNF were neutralized [6, 
10, 11]. However, in these studies cytokine activity was 
blocked by systemic administration of inhibitors, which 
may not cross the blood-brain barrier in a sufficient man-
ner (e.g., antibodies), and thus, immune mediators may 
promote the low T3 syndrome at a central level. Since IL-6 
receptor and the signal-transducing molecule gp130 are 
localized in the CNS, particularly in the hypothalamus, 
and since IL-6 synthesis is upregulated in the brain after 
TBI [42–45], it seemed reasonable to investigate a putative 
influence of this cytokine released into CSF on thyroid 
hormone metabolism. However, our data did not support 
this hypothesis. Therefore, it may well be that the release 
of IL-6 and TNF, and the low serum T3 levels are simulta-
neous but independent consequences of the acute-phase 
reaction after TBI, and that a particular, still unknown 
component of this response may be involved in the patho-
genesis of the low T3 syndrome, as suggested previously [7, 
9, 20]. A relationship between IL-10 levels and low T3 syn-
drome was also absent in another clinical study [12]. The 
lack of such correlations may also be due to an indepen-
dent pathophysiology of low T3 syndrome occurring after 
TBI, since some authors described unchanged values of 
reverse T3 [17]. However, several other reports found in-
creased concentrations of reverse T3 suggesting altered 
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hepatic thyroxin deiodinase type 1 activity similar to other 
patient groups [13, 15, 18]. Additionally, it cannot be ruled 
out that statistical significance (especially if the effects to 
be expected are moderate [7]) was missed due to a limited 
number of investigated subjects in this special group of pa-
tients. Additional mechanisms may also lead to low T3 syn-
drome following TBI. Fasting and starvation cause a 
prompt decline in serum T3 and FT3 [1], and are relevant, 
since malnutrition as well as hypercatabolism are common 
findings after severe TBI [46]. In a similar group of head-in-
jured patients, treated according to an identical therapy 
regimen on our intensive care unit [28] during the same 
study period, an initial temporary hypercatabolism was 
found. Despite early enteral feeding, positive or neutral 
nitrogen balance could not be achieved in these patients 
(unpublished results, personal communication Professor 
R. Stocker). TBI induces an increase in serum levels of epi-
nephrine, norepinephrine, and dopamine which are sug-
gested to play a role in causing low T3 syndrome and which 
may also influence cytokine levels [17, 47–49]. Thus, in this 
study a disturbed nutritional state and the sympathoadre-
nal response may both induce or aggravate a low T3 syn-
drome in the patients. Therapeutic administration of do-
pamine requires a special consideration, since 
thyroid-stimulating hormone (TSH) levels are suppressed 
during infusion [50, 51]. This was also shown in brain-in-
jured patients [13]. The situation is different for T3 and T4. 
In fact, some authors did not detect a significant decrease 
of these hormones after initiation of dopamine infusion 
[13, 50], whereas others have shown a decrease of T4 dur-
ing a newly appearing period of shock requiring additional 
dopamine treatment [51]. Thus, routine administration 
might confound our results. However, since all patients re-
ceived the same low dose during the respective study pe-
riod, we regard the impact on the results as of minor effect, 
representing a mild but inevitable bias.
The severity of thyroid hormonal disturbance was 
not predictive of the clinical outcome in severely brain-in-
jured patients, which is contrary to a previous study [17], 
but is supported by others [13, 15]. However, in an older 
study, reduction of T4 was proportional to the severity of 
coma [14]. This might be reflected by our finding that pa-
tients with a low T3-low T4 status had to be treated longer 
in the intensive care unit as compared to those with low 
T3 alone. Regarding the putative effects of low T3 syn-
drome on the damaged brain, it has been shown that tis-
sue T3 concentrations in cerebral cortex were significant-
ly lower in a group of low T3 syndrome patients compared 
with those in control patients [52]. A global reduction of 
cerebral blood flow as well as of cerebral glucose metabo-
lism was induced by hypothyroidism of short duration 
[53]. It might be hypothesized that a reduction in serum 
T3 (and T4) reduces metabolic demands in the brain fol-
lowing injury, which may be a beneficial effect, compa-
rable to the pharmacological concept underlying thera-
peutic barbiturate coma in TBI patients. On the other 
hand, since this effect is partly explained by an increased 
vascular resistance and might also result from an insuffi-
cient extraction of oxygen and glucose from the blood 
[53], these findings could as well represent an inadequate 
fulfillment of neuronal metabolic requirements. Further-
more, hypothyroidism is known to affect oligodendrogli-
al and neuronal proliferation, apoptosis, migration, and 
differentiation [54, 55]. Thus, the low T3 syndrome may 
negatively influence cerebral recovery after TBI also at 
that cellular level. Since there is an ongoing debate on the 
functional effects of the syndrome at a cellular level as 
well as on its systemic consequences (beneficial adapta-
tion vs. maladaptation), proof for any of these hypotheses 
is lacking to date. Concerning therapeutic thyroid hor-
mone replacement, it has been stated that there is no 
clear evidence that T3 or T4 treatment of the low T3 syn-
drome is disadvantageous, but there is also no certain 
proof that it is beneficial [1, 2].
Conclusion
Our data show a statistical association between the sup-
pression/recovery of cellular host defense markers and 
the severity of the low T3 syndrome after TBI. By con-
trast, a correlation of cytokine levels with the low T3 
syndrome after TBI was not found in this study. Experi-
mental studies are warranted to further elucidate this 
possible interrelation at a functional level.
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